Guangzhou Kingmed Diagnostics Group Co., Ltd. (603882.SS)
CNY 31.24
(-1.26%)
CNY 31.24
(-1.26%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 1.33 Billion CNY | -73.48% |
| 2022 | 3.97 Billion CNY | 25.68% |
| 2021 | 3.2 Billion CNY | 51.55% |
| 2020 | 2.12 Billion CNY | 165.4% |
| 2019 | 789.9 Million CNY | 36.91% |
| 2018 | 623.05 Million CNY | 19.96% |
| 2017 | 481.55 Million CNY | 25.66% |
| 2016 | 409.57 Million CNY | 36.0% |
| 2015 | 300.37 Million CNY | 136.59% |
| 2014 | 118.99 Million CNY | -5.4% |
| 2013 | 125.53 Million CNY | 28.29% |
| 2012 | 96.89 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 284.82 Million CNY | 158.43% |
| 2024 Q1 | 114.55 Million CNY | -60.72% |
| 2024 Q3 | 7.19 Million CNY | -98.68% |
| 2023 Q3 | 379.7 Million CNY | 10.55% |
| 2023 Q4 | 247.69 Million CNY | -34.77% |
| 2023 FY | - CNY | -73.48% |
| 2023 Q1 | 310.41 Million CNY | -28.08% |
| 2023 Q2 | 343.48 Million CNY | 10.65% |
| 2022 Q3 | 993.7 Million CNY | -4.01% |
| 2022 Q2 | 1.03 Billion CNY | -8.84% |
| 2022 Q1 | 1.13 Billion CNY | 49.29% |
| 2022 FY | - CNY | 25.68% |
| 2022 Q4 | 431.63 Million CNY | -56.56% |
| 2021 Q2 | 639.61 Million CNY | -4.49% |
| 2021 FY | - CNY | 51.55% |
| 2021 Q4 | 760.73 Million CNY | -3.19% |
| 2021 Q1 | 669.69 Million CNY | 18.89% |
| 2021 Q3 | 785.81 Million CNY | 22.86% |
| 2020 Q1 | 88.5 Million CNY | -22.53% |
| 2020 Q2 | 634.55 Million CNY | 616.99% |
| 2020 FY | - CNY | 165.4% |
| 2020 Q4 | 563.29 Million CNY | -5.86% |
| 2020 Q3 | 598.38 Million CNY | -5.7% |
| 2019 Q1 | 75.06 Million CNY | -24.95% |
| 2019 FY | - CNY | 36.91% |
| 2019 Q4 | 114.23 Million CNY | -40.44% |
| 2019 Q3 | 191.8 Million CNY | 7.57% |
| 2019 Q2 | 178.3 Million CNY | 137.54% |
| 2018 Q4 | 100.01 Million CNY | -6.56% |
| 2018 FY | - CNY | 19.96% |
| 2018 Q3 | 107.03 Million CNY | -18.84% |
| 2018 Q2 | 131.88 Million CNY | 309.67% |
| 2018 Q1 | 32.19 Million CNY | -63.58% |
| 2017 Q1 | 28.93 Million CNY | -69.34% |
| 2017 Q3 | 88.58 Million CNY | -28.79% |
| 2017 Q4 | 88.38 Million CNY | -0.22% |
| 2017 Q2 | 124.39 Million CNY | 329.9% |
| 2017 FY | - CNY | 25.66% |
| 2016 Q4 | 94.38 Million CNY | 28.87% |
| 2016 Q3 | 73.24 Million CNY | 0.0% |
| 2016 FY | - CNY | 36.0% |
| 2015 Q4 | 77.04 Million CNY | 0.0% |
| 2015 FY | - CNY | 136.59% |
| 2014 FY | - CNY | -5.4% |
| 2013 FY | - CNY | 28.29% |
| 2012 FY | - CNY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Shanghai Runda Medical Technology Co., Ltd. | 1.11 Billion CNY | -19.573% |
| Joinn Laboratories(China)Co.,Ltd. | 639.51 Million CNY | -108.232% |
| WuXi AppTec Co., Ltd. | 14.16 Billion CNY | 90.602% |
| Autobio Diagnostics Co., Ltd. | 1.87 Billion CNY | 28.892% |
| Thalys Medical Technology Group Inc. | -23.79 Million CNY | 5696.848% |
| Chemclin Diagnostics Co., Ltd. | 219.33 Million CNY | -507.131% |